Elite Diagnostic Limited (ELITE)
Unaudited financials for the twelve months ended June 30, 2026:

Elite Diagnostic Limited (ELITE) for the twelve months ended June 30, 2026, reported a 2% increase in Income totaling $867.30 million compared to $853.82 million in the corresponding period last year. Income for the fourth quarter had a 4% decrease to close at $216.52 million compared to $225.00 million for the comparable quarter of 2025.

Direct costs amounted to $197.33 million (2025: $211.44 million), this represents a decrease of 7% year over year. Consequently, gross profit increased by 4% to $669.97 million compared to $642.39 million for the twelve months ended June 30, 2025. The company booked gross profit of $167.27 million for the fourth quarter versus $172.85 million reported for the similar quarter of 2025.

Administrative expenses increased by 3% to close at $413.49 million (2025: $400.90 million), while Depreciation increased by 5% from $170.11 million in 2025 to $179.38 million in the period under review. As a result, operating profit for the twelve months ended June 30, 2026, amounted to $77.09 million, a 5% increase relative to $73.31 million reported in 2025.

Gain on foreign exchange for the twelve months ended June 30, 2026, amounted to $3.16 million (2025: $2.62 million), while other income was $1.28 million (2025: $133,000). Finance costs totaled $48.31 million, a 23% increase from the corresponding period last year (2025: $39.14 million), reflecting new borrowings drawn to fund capital expansion.

Profit Before Tax for the twelve months ended June 30, 2026, amounted to $33.21 million, a 10% decrease relative to $36.92 million reported in 2025. Profit Before Tax for the fourth quarter amounted to $6.82 million (2025: $14.00 million).

Income Tax for the twelve months ended June 30, 2026, had a 65% decrease to reach $1.71 million (2025: $4.90 million). As a result, Net Profit for the twelve months amounted to $31.51 million, a 2% decrease from the $32.02 million reported in 2025. For the fourth quarter, Net Profit was $5.98 million (2025: $13.84 million).

Consequently, Earnings Per Share for the twelve months amounted to $0.09 (2025: EPS: $0.09), while Earnings Per Share for the quarter totaled $0.02 (2025: EPS: $0.04). The twelve-month trailing EPS was $0.09, and the number of shares used in these calculations was 353,400,000.

Notably, ELITE’s stock price closed the trading period on August 14, 2026, at a price of $1.32 with a corresponding P/E ratio of 14.81x.

Balance Sheet Highlights

The company’s assets totaled $1.31 billion (2025: $1.11 billion). The movement in total assets was mainly attributable to a 38% increase in ‘Property, plant and equipment’ amounting to $968.13 million (2025: $701.16 million) following the acquisition of a property for the planned relocation of operations, which was partly offset by a 45% decline in ‘Cash and cash equivalents’ amounting to $124.17 million (2025: $225.55 million).

Shareholders’ equity was $574.51 million (2025: $543.01 million), representing a book value per share of $1.63 (2025: $1.54).

Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.

Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.